

**IL18 Antibody (Center) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP10957b****Specification**

---

**IL18 Antibody (Center) Blocking peptide - Product Information**Primary Accession [Q14116](#)**IL18 Antibody (Center) Blocking peptide - Additional Information****Gene ID** 3606**Other Names**

Interleukin-18, IL-18, Ibctadekin, Interferon gamma-inducing factor, IFN-gamma-inducing factor, Interleukin-1 gamma, IL-1 gamma, IL18, IGIF, IL1F4

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**IL18 Antibody (Center) Blocking peptide - Protein Information****Name** IL18 ([HGNC:5986](#))**Synonyms** IGIF, IL1F4**Function**

Pro-inflammatory cytokine primarily involved in epithelial barrier repair, polarized T-helper 1 (Th1) cell and natural killer (NK) cell immune responses (PubMed: [10653850](http://www.uniprot.org/citations/10653850)). Upon binding to IL18R1 and IL18RAP, forms a signaling ternary complex which activates NF-kappa-B, triggering synthesis of inflammatory mediators (PubMed: [14528293](http://www.uniprot.org/citations/14528293), PubMed: [25500532](http://www.uniprot.org/citations/25500532), PubMed: [37993714](http://www.uniprot.org/citations/37993714)). Synergizes with IL12/interleukin-12 to induce IFNG synthesis from T-helper 1 (Th1) cells and natural killer (NK) cells (PubMed: [10653850](http://www.uniprot.org/citations/10653850)). Involved in transduction of inflammation downstream of pyroptosis: its mature form is specifically released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed: [33883744](http://www.uniprot.org/citations/33883744)).

**Cellular Location**

Cytoplasm, cytosol. Secreted. Note=The precursor is cytosolic (PubMed:33883744). In response to inflammasome-activating signals, cleaved and secreted (PubMed:33883744, PubMed:37993712, PubMed:37993714). Mature form is secreted and released in the extracellular milieu by passing through the gasdermin-D (GSDMD) pore (PubMed:33883744, PubMed:37993714). In contrast, the precursor form is not released, due to the presence of an acidic region that is proteolytically removed by CASP1, CASP4 or CASP5 during maturation (PubMed:33883744, PubMed:37993714). The secretion is dependent on protein unfolding and facilitated by the cargo receptor TMED10 (PubMed:32272059).

**Tissue Location**

[Isoform 2]: Expressed in ovarian carcinoma but undetectable in normal ovarian epithelial cells. Resistant to proteolytic activation by caspase-1 and -4

**IL18 Antibody (Center) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**IL18 Antibody (Center) Blocking peptide - Images****IL18 Antibody (Center) Blocking peptide - Background**

The protein encoded by this gene is a proinflammatory cytokine. This cytokine can induce the IFN-gamma production of T cells. The combination of this cytokine and IL12 has been shown to inhibit IL4 dependent IgE and IgG1 production, and enhance IgG2a production of B cells. IL-18 binding protein (IL18BP) can specifically interact with this cytokine, and thus negatively regulate its biological activity.

**IL18 Antibody (Center) Blocking peptide - References**

Hernesniemi, J.A., et al. Eur. J. Clin. Invest. 40(11):994-1001(2010) Hartford, M., et al. Arterioscler. Thromb. Vasc. Biol. 30(10):2039-2046(2010) Romero, R., et al. Am. J. Obstet. Gynecol. 203 (4), 361 (2010) :Franchim, C.S., et al. Hypertens Pregnancy (2010) In press :Ayaz, L., et al. Fertil. Steril. (2010) In press :